- Home
- BBWI vs AXSM Comparison
BBWI vs AXSM Comparison
Compare BBWI & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBWI
- AXSM
- Stock Information
- Founded
- BBWI 1963
- AXSM 2012
- Country
- BBWI United States
- AXSM United States
- Employees
- BBWI N/A
- AXSM N/A
- Industry
- BBWI Clothing/Shoe/Accessory Stores
- AXSM Biotechnology: Pharmaceutical Preparations
- Sector
- BBWI Consumer Discretionary
- AXSM Health Care
- Exchange
- BBWI Nasdaq
- AXSM Nasdaq
- Market Cap
- BBWI 5.0B
- AXSM 5.9B
- IPO Year
- BBWI N/A
- AXSM 2015
- Fundamental
- Price
- BBWI $15.52
- AXSM $150.62
- Analyst Decision
- BBWI Buy
- AXSM Strong Buy
- Analyst Count
- BBWI 18
- AXSM 20
- Target Price
- BBWI $28.28
- AXSM $176.00
- AVG Volume (30 Days)
- BBWI 10.0M
- AXSM 591.4K
- Earning Date
- BBWI 11-20-2025
- AXSM 11-03-2025
- Dividend Yield
- BBWI 5.14%
- AXSM N/A
- EPS Growth
- BBWI N/A
- AXSM N/A
- EPS
- BBWI 3.30
- AXSM N/A
- Revenue
- BBWI $7,354,000,000.00
- AXSM $561,263,000.00
- Revenue This Year
- BBWI $4.09
- AXSM $63.66
- Revenue Next Year
- BBWI $2.75
- AXSM $54.46
- P/E Ratio
- BBWI $4.72
- AXSM N/A
- Revenue Growth
- BBWI N/A
- AXSM 65.83
- 52 Week Low
- BBWI $14.28
- AXSM $75.56
- 52 Week High
- BBWI $41.87
- AXSM $151.33
- Technical
- Relative Strength Index (RSI)
- BBWI 17.50
- AXSM 71.42
- Support Level
- BBWI $14.28
- AXSM $142.51
- Resistance Level
- BBWI $22.43
- AXSM $149.46
- Average True Range (ATR)
- BBWI 0.82
- AXSM 5.44
- MACD
- BBWI -0.74
- AXSM 0.62
- Stochastic Oscillator
- BBWI 12.60
- AXSM 99.12
About BBWI Bath & Body Works Inc.
Bath & Body Works is a specialty home fragrance and fragrant body care retailer operating under the Bath & Body Works, C.O. Bigelow, and White Barn brands. The company generates most of its business in North America, with just 5% of sales from international markets in fiscal 2024. For fiscal 2024, 76% of sales stemmed from the brick-and-mortar network (which was composed of more than 1,800 retail stores), similar to 2023 levels, as consumer shopping patterns remained to normal. Future growth is expected from store upgrades, digital and international channels, as well as adjacent category expansions like hair and laundry.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.